الصفحة الرئيسية>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>CI 972 (anhydrous)

CI 972 (anhydrous)

رقم الكتالوجGC35693

CI 972 (لا مائي) هو مثبط قوي ، فعال عن طريق الفم ، وتنافسي من فوسفوريلاز نيوكليوزيد البيورين (PNP) (Ki \u003d 0.83 ميكرومتر) قيد التطوير كعامل مثبط للمناعة انتقائي للخلايا التائية.

Products are for research use only. Not for human use. We do not sell to patients.

CI 972 (anhydrous) التركيب الكيميائي

Cas No.: 115787-68-3

الحجم السعر المخزون الكميّة
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CI 972 anhydrous is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (Ki=0.83 μM) under development as a T cell-selective immunosuppressive agent[1][2]. Ki: 0.83 μM (PNP)[1]

CI 972 anhydrous (5-150 mg/kg; p.o.) produces dose-dependent elevation of plasma inosine one hour after administration to rats[1].

[1]. Gilbertsen RB, et al. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor. Adv Exp Med Biol. 1991;309A:41-4. [2]. Gilbertsen RB,et al. Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1351-8.

مراجعات

Review for CI 972 (anhydrous)

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CI 972 (anhydrous)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.